Ascendis Pharma A/S (NASDAQ:ASND) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in a research report sent to investors on Monday,Benzinga reports. They currently have a $200.00 price target on the biotechnology company's stock.

Other equities analysts have also recently issued reports about the stock. Morgan Stanley raised shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $180.00 to $250.00 in a research report on Monday, May 5th. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Evercore ISI upped their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Royal Bank of Canada raised their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and an average target price of $216.07.

Ascendis Pharma A/S Trading Up 0.0%

Ascendis Pharma A/S stock traded up $0.06 during mid-day trading on Monday, hitting $157.60. The stock had a trading volume of 502,233 shares, compared to its average volume of 494,382. The stock has a market capitalization of $9.61 billion, a PE ratio of -22.20 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The stock has a 50-day simple moving average of $157.15 and a two-hundred day simple moving average of $142.36.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analysts' expectations of $98.56 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. T. Rowe Price Investment Management Inc. raised its holdings in shares of Ascendis Pharma A/S by 54.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after acquiring an additional 960,504 shares during the last quarter. Capital International Investors grew its stake in shares of Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after acquiring an additional 753,859 shares during the period. RA Capital Management L.P. raised its holdings in Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after acquiring an additional 402,316 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at approximately $51,029,000. Finally, Vestal Point Capital LP increased its stake in Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock worth $71,588,000 after acquiring an additional 270,000 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.